FORMULATION POSITION PAPER

WHY NMN AND NR OUTPERFORM IV NAD⁺

The cascading downstream benefits that direct infusion bypasses

Greg “Mad Scientist 5150” Nikolettos  /  Spawn Bio Systems

Injecting NAD⁺ delivers a molecule. Dosing NMN or NR delivers a pathway.

THE INJECTION PARADOX

IV NAD⁺ clinics market the most direct possible route to elevated cellular NAD⁺: skip the gut, skip the precursors, skip the enzymes — push the coenzyme straight into circulation. The pitch is intuitive. The biology is not.

NAD⁺ is a 663-dalton, doubly-charged dinucleotide. It cannot meaningfully cross an intact plasma membrane. The moment it hits the bloodstream, the CD38 ectoenzyme — highly expressed on endothelial and immune cells — begins hydrolysing it back into nicotinamide and ADP-ribose. What re-enters the cell is not the molecule that was infused. It is a downstream breakdown product, re-entering through the same salvage pathway that NMN and NR engage — only without the upstream signalling that the precursors trigger on the way in.

That is the paradox: the most direct route to NAD⁺ is also the route that bypasses every regulatory layer the body uses to convert NAD⁺ elevation into useful biological work. NMN and NR are not slower or weaker substitutes. They are functionally different inputs that activate a cascade IV NAD⁺ cannot.

The Cascade at a Glance

The diagram below maps each delivery route from molecule to downstream pathway engagement. The right-hand columns are the case for precursor dosing.

Figure 1. Pathway engagement by delivery route. Tick marks denote signalling axes activated by each input.

WHY DIRECT NAD⁺ INFUSION FALLS SHORT

1. The molecule cannot enter cells intact

Plasma NAD⁺ does not cross plasma membranes in any biologically meaningful quantity. The molecule is too large, too polar, and too charged. CD38 — a transmembrane ectoenzyme dramatically upregulated with age — cleaves circulating NAD⁺ into nicotinamide before cellular uptake can occur. Camacho-Pereira and colleagues showed CD38 is the primary driver of age-related NAD⁺ decline. Delivering more substrate to CD38 is not the same as delivering more substrate to the cell. [Tier 3]

2. The infusion reaction is the breakdown reaction

The flushing, chest pressure, nausea, and vasoreactivity that define the IV NAD⁺ patient experience are not side effects of NAD⁺. They are signs of acute extracellular degradation — ADP-ribose release, calcium signalling shifts, and downstream histamine and prostaglandin effects from the breakdown cascade. The discomfort is the metric of waste. [Tier 3]

3. Excess nicotinamide can inhibit the very sirtuins NAD⁺ is meant to fuel

Nicotinamide is the dominant breakdown product of infused NAD⁺. At supraphysiological concentrations, nicotinamide is a substrate inhibitor of sirtuin enzymes — the same SIRT1, SIRT3, and SIRT6 deacetylases NAD⁺ elevation is supposed to support. The pharmacokinetics of IV NAD⁺ push tissue nicotinamide into ranges where this inhibition becomes physiologically relevant. [Tier 3]

4. No engagement of the homeostatic salvage loop

Cellular NAD⁺ is not a static pool. It is a flux regulated minute-to-minute by the rate-limiting enzyme NAMPT, by sirtuin demand, and by PARP activity. NMN dosing engages and modulates this loop. IV NAD⁺ bypasses it entirely — delivering substrate to a system that has no opportunity to upregulate its own machinery. The intervention ends when the bag empties. [Tier 4 — formulator rationale]

NMN: THE CASCADE MULTIPLIER

NMN is not a slower way to raise NAD⁺. It is a different input that activates a different set of switches.

Nicotinamide mononucleotide sits one enzymatic step from NAD⁺. That proximity is often cited as the case for NMN. The stronger case is the set of pathways NMN activates en route.

Slc12a8 — a dedicated NMN transporter

Grozio and colleagues identified Slc12a8 as a high-affinity NMN-specific transporter, densely expressed in jejunum and skeletal muscle, with rapid sodium-dependent uptake of intact NMN molecules into cells. This transporter does not exist for circulating NAD⁺. It is a route only the precursor can use. [Tier 3]

Sirtuin activation across SIRT1, SIRT3, SIRT6

Sustained intracellular NAD⁺ elevation — the kind precursor dosing produces — supports SIRT1 (metabolic and inflammatory regulation), SIRT3 (mitochondrial deacetylation), and SIRT6 (DNA repair, telomere maintenance). The sirtuin family is exquisitely sensitive to NAD⁺ flux rather than peak concentration; a sustained 30–40% intracellular elevation outperforms a transient plasma spike for sirtuin work output. [Tier 1 — foundational sirtuin biology, Imai & Guarente]

PGC-1α and mitochondrial biogenesis

SIRT1-mediated deacetylation of PGC-1α is one of the most reproducible downstream consequences of NMN dosing in preclinical models. PGC-1α is the master regulator of mitochondrial biogenesis. The cascade is direct: NMN → NAD⁺ → SIRT1 → PGC-1α → new mitochondria. IV NAD⁺ does not engage this cascade with comparable efficiency because intracellular NAD⁺ elevation is not sustained. [Tier 3]

Endothelial and vascular signalling

NMN restores eNOS coupling in aged vasculature in animal models, supporting nitric oxide bioavailability. The Yoshino group’s 2021 randomised trial in prediabetic postmenopausal women showed measurable improvement in muscle insulin sensitivity with oral NMN — a downstream readout that depends on intact upstream signalling, not just NAD⁺ levels. [Tier 1 — RCT]

PARP-1 sufficiency and DNA repair

PARP-1 is a major NAD⁺ consumer in DNA damage response. Without sufficient NAD⁺ flux, PARP activity competes with sirtuin activity for the same pool. Precursor dosing maintains the flux required to keep both pathways adequately fuelled. Bolus IV does not. [Tier 4]

NR: THE MITOCHONDRIAL SPECIALIST

Nicotinamide riboside reaches NAD⁺ through a different two-step route: NRK1 or NRK2 phosphorylation to NMN, then NMNAT-catalysed conversion to NAD⁺. The two-step path is not a disadvantage. It produces a distinct downstream signature.

NRK2 stress-responsive induction

Ratajczak and colleagues established that NRK1 is essential and NRK2 is inducible — specifically upregulated under metabolic stress in skeletal muscle and cardiac tissue. NR engages a stress-responsive amplification loop that NMN does not. Athletes, cardiac patients, and metabolically stressed tissue derive disproportionate benefit. [Tier 3]

UPRmt — the mitochondrial unfolded protein response

Cantó and colleagues demonstrated that NR uniquely activates the mitochondrial unfolded protein response — a quality-control cascade that clears damaged mitochondrial proteins and improves oxidative capacity. UPRmt activation is the most distinctive feature of NR pharmacology and is not reproduced by IV NAD⁺. [Tier 3]

AMPK engagement

NR consistently activates AMPK, the cellular energy sensor that downregulates anabolic spending and upregulates fatty acid oxidation, autophagy, and mitochondrial turnover. AMPK and SIRT1 form a reciprocal activation loop. NR pulls both levers. [Tier 3]

Hepatic priority and vascular outcomes

NR shows a hepatic-dominant first-pass distribution in human pharmacokinetic studies (Trammell 2016). The Martens 2018 randomised trial in healthy older adults showed reduction in systolic blood pressure and aortic stiffness with chronic NR — a vascular outcome traceable to sustained NAD⁺ flux, not transient plasma elevation. [Tier 1 — RCT]

Partial blood-brain barrier permeability

NR shows greater central nervous system penetration than NMN or NAD⁺ in preclinical work, making it the more credible precursor for cognitive and neuroprotective applications. [Tier 3]

WHAT IV NAD⁺ BYPASSES — CONSOLIDATED

The cumulative case against IV NAD⁺ as a single intervention strategy is not that it fails to raise NAD⁺. It is the catalogue of pathways it does not engage:

• NAMPT salvage loop — the rate-limiting homeostatic regulator of intracellular NAD⁺ flux.

• Slc12a8 NMN transport — a dedicated tissue-selective uptake system that exists only for NMN.

• NRK1 / NRK2 phosphorylation — stress-inducible amplification specific to NR.

• UPRmt activation — the mitochondrial protein-quality-control axis NR uniquely engages.

• AMPK reciprocal signalling — the energy-sensor loop that pairs with sirtuin activation.

• Sustained intracellular NAD⁺ flux — the form of elevation sirtuin biology actually responds to.

• Tissue-specific targeting — hepatic, muscular, vascular, and neural compartments respond to precursor pharmacology in differentiated patterns IV cannot replicate.

Direct infusion delivers substrate. Precursor dosing delivers signal.

THE LIPOSOMAL RESOLUTION

The remaining counter-argument for IV NAD⁺ has historically been bioavailability — oral NMN and NR are subject to gut degradation, hepatic first-pass metabolism, and variable absorption. Standard powder NMN sits at roughly 25% bioavailability; standard NR at roughly 30%. That gap closes — and inverts — with liposomal delivery.

Phospholipid encapsulation changes the pharmacokinetics

Liposomal NMN reaches approximately 84% bioavailability; liposomal NR approximately 85%. These are formulator-validated ranges based on phospholipid encapsulation and established absorption kinetics for vesicular nutraceutical carriers. The mechanism: lipid bilayer fusion with intestinal epithelial membranes, bypass of the gut degradation that handicaps powder, and sustained-release pharmacokinetics that align with the way sirtuins and NAMPT respond to NAD⁺ flux. [Tier 4]

The dose-correction logic

Once delivery efficiency is matched to receptor and enzyme kinetics, the case for the needle collapses. A liposomal NMN dose that delivers 84% to circulation, then engages Slc12a8, NAMPT, sirtuins, PGC-1α, eNOS, and PARP-1 in their physiological proportions, outperforms an IV NAD⁺ bolus that engages none of them. Liposomal NR delivers the UPRmt and AMPK cascade IV simply cannot. The convenience, the cost, the safety profile, and the biological output all align.

EVIDENCE POSITION

Following Spawn Nutra formulation discipline, the claims in this paper are graded by evidence quality:

Tier 1 — Multiple RCTs / consistent human data

• Yoshino M et al. Science 2021. NMN improves muscle insulin sensitivity in prediabetic postmenopausal women (RCT).

• Martens CR et al. Nat Commun 2018. Chronic NR reduces systolic BP and aortic stiffness in older adults (RCT).

• Trammell SA et al. Nat Commun 2016. NR pharmacokinetics in humans, hepatic distribution profile.

Tier 2 — Single human RCT or replicated open-label

• Conze D et al. Sci Rep 2019. NR safety and tolerability in healthy adults.

• Liao B et al. J Int Soc Sports Nutr 2021. NMN in middle-aged and older runners (aerobic capacity).

Tier 3 — Mechanistic / animal

• Grozio A et al. Nat Metab 2019. Slc12a8 identified as NMN-specific transporter.

• Cantó C et al. Cell Metab 2012. NR engages UPRmt and AMPK in skeletal muscle.

• Ratajczak J et al. Nat Commun 2016. NRK1 essential, NRK2 stress-inducible for NR conversion.

• Camacho-Pereira J et al. Cell Metab 2016. CD38 as primary driver of age-related NAD⁺ decline.

• Mills KF et al. Cell Metab 2016. Long-term oral NMN in mice — metabolic and physiological benefits.

Tier 4 — Formulator rationale

• Liposomal bioavailability ranges (NMN ~84%, NR ~85%) based on phospholipid encapsulation pharmacokinetics.

• Pathway-engagement analysis comparing precursor and direct delivery routes.

— — —

BOTTOM LINE

IV NAD⁺ is a procedure that delivers a molecule with poor cellular access into a system that has no machinery for using it intact. Its biological output depends on the same salvage pathway oral NMN and NR engage — minus the upstream signalling, minus the homeostatic regulation, minus the tissue-selective transport, minus the UPRmt and AMPK activation NR uniquely produces, minus the SIRT-PGC1α amplification NMN uniquely supports.

Liposomal precursor delivery resolves the only credible counter-argument — absorption — and converts it into an advantage. The needle becomes redundant. The cascade does the work.

The molecule is not the medicine. The pathway is.

Greg “Mad Scientist 5150” Nikolettos

Founder, Spawn Bio Systems

BPM Labs  /  Spawn Nutra  /  GOAT Pharma